ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

Nimer to Lead Miami Sylvester Cancer Center

March 9, 2012

Drug Effectiveness Weakens After Three Years, Study Says

May 27, 2011

Panel to Hear Innovation Reports

August 26, 1988

DCT Board Okays Concepts Of Four New Grant Projects, Four Competitive Contract Delays Chlordane Study

March 9, 1984

Data Presented At Scientific Meetings Can Have Impact On Patient Treatment

March 31, 2006